Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiplatelet therapy: Aspirin in the elderly

Literature DB >> 28795687

Antiplatelet therapy: Aspirin in the elderly - tailored approaches ahead?

Victor Serebruany¹, Elena Golukhova².

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2017 PMID： 28795687 DOI： 10.1038/nrcardio.2017.117

Source DB: PubMed Journal: Nat Rev Cardiol ISSN： 1759-5002 Impact factor: 32.419

Keyword Cloud
References

× No keyword cloud information.

10 in total

1. Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials.

Authors: Thomas A Marciniak; Vasily Cherepanov; Elena Golukhova; Moo Hyun Kim; Victor Serebruany
Journal: JAMA Intern Med Date: 2016-02 Impact factor: 21.873

2. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.

Authors: Victor L Serebruany; Alex N Pokov; Alex I Malinin; Christopher O'Connor; Deepak L Bhatt; Jean-Francois Tanguay; David C Sane; Charles H Hennekens
Journal: Am Heart J Date: 2006-01 Impact factor: 4.749

Review 3. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.

Authors: C H Hennekens; J E Buring; P Sandercock; R Collins; R Peto
Journal: Circulation Date: 1989-10 Impact factor: 29.690

Review 4. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?

Authors: Victor L Serebruany
Journal: Am J Med Date: 2006-02 Impact factor: 4.965

5. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.

Authors: Victor L Serebruany; Steven R Steinhubl; Peter B Berger; Alex I Malinin; Jeffrey S Baggish; Deepak L Bhatt; Eric J Topol
Journal: Am J Cardiol Date: 2005-05-15 Impact factor: 2.778

10. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.

Authors: Linxin Li; Olivia C Geraghty; Ziyah Mehta; Peter M Rothwell
Journal: Lancet Date: 2017-06-13 Impact factor: 79.321

10 in total

Antiplatelet therapy: Aspirin in the elderly - tailored approaches ahead?

1. Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials.

2. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.

Review 3. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.

Review 4. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?

5. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.

Review 6. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Review 7. Aspirin Use for the Primary Prevention of Cardiovascular Disease in the Elderly.

8. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Review 9. Novel antiplatelet agents in acute coronary syndrome.

10. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.